Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Titis Sekar Humani"'
Autor:
Rien Ritawidya, Hendris Wongso, Nurmaya Effendi, Anung Pujiyanto, Wening Lestari, Herlan Setiawan, Titis Sekar Humani
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 13, Iss 4, Pp 701-711 (2023)
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several prom
Externí odkaz:
https://doaj.org/article/e7563736b1504f889fdfab272e566029
Publikováno v:
Journal of Mathematical and Fundamental Sciences, Vol 49, Iss 3, Pp 258-268 (2017)
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profile and tumor penetration, and potential for eliciting host antibody responses. F(ab’)2 fragments smaller than intact monoclonal antibodies that still
Externí odkaz:
https://doaj.org/article/ee85ea80949f4c5b947b7a11b3f4da66
Autor:
Rien Ritawidya, Citra Rezza Aurora Putri Palangka, Titis Sekar Humani, Veronika Yulianti Susilo, Ilma Darojatin, Anung Pujiyanto
Publikováno v:
Indonesian Journal of Pharmacy. :333-352
Somatostatin receptors (SSTRs) are overexpressed in a wide variety of cancers such as neuroendocrine tumors (NETs), but the expression in normal cells is relatively low. Therefore, SSTRs serve a potential target for molecular imaging and therapeutic
Publikováno v:
PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in Medicine and Biomedical Applications.
The aim of this study was to investigate the effect of different radiopharmaceutical drugs on the performance of translation method of time-integrated activity coefficient (TIAC) from mice to humans. 177Lu-DOTA-Trastuzumab (Tras) percentage of inject
Publikováno v:
Journal of Physics: Conference Series. 1505:012046
The accuracy of radiopharmaceutical activity which will be administered to the patients is very important in nuclear medicine, especially in the case of therapeutical procedure. Hence, all safety aspects should be considered, including the standardiz
Autor:
Abdul Mutalib, Titis Sekar Humani, Basuki Hidayat, Karyadi Karyadi, Sri Aguswarini, Martalena Ramli, Cecep Taufik Rustendi, Cahya Nova Ardiyatno, Johan S. Masjhur, Rien Ritawidya, Muhammad Subur
Publikováno v:
ITB Journal of Sciences. 44:333-345
Autor:
Sutari Sutari, Triningsih Triningsih, Titis Sekar Humani, Ratna Dini Haryuni, Martalena Ramli, Rien Ritawidya
Publikováno v:
Journal of Mathematical and Fundamental Sciences, Vol 49, Iss 3, Pp 258-268 (2017)
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profile and tumor penetration, and potential for eliciting host antibody responses. F(ab’) 2 fragments smaller than intact monoclonal antibodies that stil
Autor:
Abdul Mutalib, Veronika Yulianti Susilo, Martalena Ramli, Karyadi, Basuki Hidayat, Titis Sekar Humani, Johan S. Masjhur, Nur Rahmah Hidayati, Sutari, Triningsih, Herry Sastramihardja, Sri Setyowati, Stepanus Massora, Sri Aguswarini
Publikováno v:
Jurnal Sains dan Teknologi Nuklir Indonesia. 16:105
STUDI AWAL ESTIMASI DOSIS INTERNAL 177 Lu-DOTA TRASTUZUMAB PADA MANUSIA BERBASIS UJI BIODISTRIBUSI PADA MENCIT. Radiofarmaka baru untuk pengobatan penyakit kanker payudara tipe HER-2, 177 Lu-DOTA Trastuzumab, telah berhasil diproduksi oleh Pusat Tekn
Publikováno v:
Atom Indonesia. 41:17
Nimotuzumab is a humanized monoclonal antibody (mAb), a potential anticancer against epidermal growth factor receptor (EGFR)overexpressed by glioma, head and neck, lung, ovarium, and colon cancers. The combination of its use with both external and in